drugset / Trial / NCT01054170

Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01054170

Phase 2 Completed 52 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the study is to evaluate structural changes effected by AD9668 in the airways of adults with Chronic Obstructive Pulmonary Disease (COPD) by Multi-Slice Computed Tomography (MSCT)

Timeline

Start
2010-01
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Alvelestat Small molecule 60 mg Oral